Dr. Ory Wiesel of Maimonides Medical Center in Brooklyn, NY has begun a new clinical trial to study COVID-19 patients treated with Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT).Brief Summary:This study is a prospective randomized...
According to the World Health Organization (WHO), researchers at the Sixth Medical Center of PLA General Hospital, in Bejing, China and the Wuhan Huoshenshan Hospital in Wuhan City, China have begun a clinical trial entitled, "Efficacy and Safety of...
Thomas E Serena, MD of the SerenaGroup, Inc. with the Wound Treatment Center at Opelousas General Hospital in Louisiana have begun a new clinical trial to study COVID-19 patients treated with Hyperbaric Oxygen Therapy under Compassionate Care Basis.Study...
Amir Hadanny, MD and Shai Efrati, MD of The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center (the largest hyperbaric treatment center worldwide) in Be'er Ya'akov, Israel has begun a new clinical trial to study the treatment of...
Jean-Eric Blatteau, MD, PhD of Sainte Anne Military Teaching Hospital in Toulon, France has begun a new clinical trial to study the treatment of COVID-19 patients using Hyperbaric Oxygen Therapy. Several patients with hypoxaemic SARS-CoV2 pneumonia were...
Dr. Jeffery S Kuo is the Lead Investigator of the latest clinical trial studying the treatment of COVID-19 patients with Hyperbaric Oxygen Therapy. The study will be based out of Ochsner Medical Center in New Orleans, Louisiana. Patients who meet...
April 2, 2020, Dr. David Lee posted a new clinical trial on the NIH Clinical Trials website to study the use of Hyperbaric Oxygen Therapy (HBOT) to treat COVID-10. The study is listed as "Not Recruiting Yet," but has an estimated completion date of July 2020. ...
Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atm for the treatment of various emergent medical conditions including carbon monoxide poisoning. The most commonly associated complication of HBOT is middle ear barotrauma (MEB) which occurs when the eustachian tube does not allow air to enter the middle ear space to equalize the pressure between the ambient environment and the inner ear. Patients experiencing MEB usually feel pressure or pain in their ear(s). The spectrum of symptoms ranges from sensation of ear fullness and muffled hearing to severe pain, vertigo and tympanic membrane rupture. HBOT has not been studied. The investigators plan to perform a randomized double blind placebo control trial to determine if pseudoephedrine is effective in decreasing the rate of MEB during HBOT.
COVID-19 may cause severe pneumonitis that require ventilatory support in some patients, the ICU mortality is as high as 62%. Hospitals do not have enough ICU beds to handle the demand and to date there is no effective cure. We explore a treatment administered in a randomized clinical trial that could prevent ICU admission and reduce mortality. The overall hypothesis to be evaluated is that HBO reduce mortality, increase hypoxia tolerance and prevent organ failure in patients with COVID19 pneumonitis by attenuating the inflammatory response.
Middle ear barotrauma (MEB) is the most common complication during hyperbaric oxygen therapy
(HBOT). Though Valsalva and Toynbee maneuvers have been proposed to prevent MEB, still some
patients discontinue HBOT due to severe otalgia, hemorrhage or perforation of tympanic
membrane associated with HBOT. Currently, there is no optimal prophylactic management for MEB
associated with HBOT. The aim of this protocol is to investigate the efficacy of
self-acupressure therapy on MEB associated with HBOT.
